Drug profile · INN
tocilizumab
ACTEMRA
tocilizumab (ACTEMRA) is a interleukin-6 receptor alpha subunit inhibitor. Associated with Hoffmann-La Roche. Route of administration: injection. Current US regulatory status: approved.
Drug details — tocilizumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 78
- Data quality
- 0.84
Quick answer
tocilizumab (ACTEMRA) is a interleukin-6 receptor alpha subunit inhibitor. Associated with Hoffmann-La Roche. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-6 receptor alpha subunit inhibitor
Primary target: Interleukin-6 receptor subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tocilizumab?
tocilizumab (ACTEMRA) is a interleukin-6 receptor alpha subunit inhibitor. Associated with Hoffmann-La Roche. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for tocilizumab?
ACTEMRA is a marketed brand name for tocilizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tocilizumab?
tocilizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.